Eric Topol is a cardiologist, founder of the Scripps Research Translational Institute in California and one of the most cited physicians in the world. His book Super Agers: An Evidence-Based Approach to Longevity was published by Simon and Schuster in May 2025 and became a New York Times bestseller. In September 2026 it reached Czech readers as Superlétí.
The subtitle promises an evidence-based approach, and that is the yardstick we read it by. We do not ask whether Topol is famous. We ask which of his claims stand on large studies, where he runs ahead of the data, and what a reader who tracks their own health numbers can take from it.
What Super Agers is about, and what it is not
The book is not a manual of routines. It is an argument. Topol holds that the three diseases that shorten healthy life the most, cardiovascular disease, cancer and neurodegeneration, share one feature: they develop for decades before the first symptoms. And that in that window we can now detect them, measure them and often slow them down. The goal is not to live longer at any cost, but to extend healthspan, the years lived in good health.
The text has four parts. The first opens with the stories of two patients around ninety: one aged well through luck and lifestyle, the other through intensive modern medicine, followed by chapters on genes and on lifestyle. The second part walks through the chronic killers one by one: obesity and diabetes, heart and vessels, cancer and neurodegeneration, always asking what can be caught early. The third and strongest part covers treating rare diseases, the immune system, the fight against infections and care for mental health. The fourth looks ahead to how ageing itself is being reshaped.
Running through all of it are five dimensions Topol uses as a frame: lifestyle, cells, omics (the large-scale measurement of genes, proteins and metabolites), artificial intelligence, and drugs with vaccines.
Three ideas with the strongest support
Inflammation and immunity as the common denominator. Topol describes inflammaging, a chronic low-grade inflammation that grows with age and drives most diseases of civilisation. The most surprising evidence for the role of immunity came from Wales, in a paper published in Nature in 2025. A local rule based on date of birth meant that only people born after a certain day could receive the shingles vaccine, which created a natural experiment. Over seven years, the vaccinated had roughly a fifth fewer new dementia diagnoses. It does not prove that the virus causes dementia, but it is the strongest signal we have so far on the link between infection, immunity and the brain.
Prevention by data, not by age. Instead of blanket check-ups by the calendar, Topol proposes measuring an individual’s risk: polygenic scores, blood markers of inflammation and lipids, and newly, organ clocks. A Stanford study in Nature (2023) showed that the biological age of individual organs can be estimated from proteins in the blood, and that about a fifth of people have one organ ageing markedly faster. That acceleration predicts disease of the organ and mortality. It is still research, but the direction is clear: instead of “you are fifty, come for a check-up” we get “your kidneys look like a sixty-year-old’s, let us look at them”.
Drugs that do more than expected. The SELECT trial in the New England Journal of Medicine (2023) followed more than 17,000 people with obesity but without diabetes. Semaglutide, a GLP-1 drug, cut the risk of major cardiovascular events by a fifth. Topol concludes that these drugs dampen inflammation and may have a broader role in prevention. Caution is warranted here: these were people with obesity, not healthy readers.
Eyting et al., Nature 2025. The difference corresponds to roughly 3.5 percentage points of absolute risk over seven years. An observation from a natural experiment, not a randomised trial.
The lesson of the Wellderly study: it is not the genes
Topol has one advantage other authors lack: his own data. In the Wellderly study he had the whole genomes of 1,354 people over 80 sequenced, none of whom had ever had a serious chronic disease. The expectation was that protective variants, “longevity genes”, would turn up. They did not. The healthy eighty-year-olds merely carried slightly fewer risk variants for Alzheimer’s disease and coronary heart disease, and otherwise nothing special.
It is an unassuming but important conclusion for the whole book. Healthy ageing is not a genetic lottery. It is the result of what a person does over decades, and of whether disease is caught in time. For the reader it means a genetic test is useful for estimating risk, but it neither saves nor condemns anyone.
Where the book loses ground
Density. The original runs to more than 460 pages and reviews in the professional press describe a “dense, at times technical and occasionally repetitive” text for the health-literate reader. The chapters on omics and immunity need patience. Anyone looking for brief instructions will be disappointed.
American healthcare. Many recommendations assume you can order blood tests, imaging and genetics at your own discretion. In most European systems part of that is out of pocket, and organ clocks or proteomic panels are not routinely available at all yet.
Optimism about artificial intelligence. Topol is a long-standing advocate of AI in medicine and gives it a large role in predicting disease. The studies he cites are mostly retrospective. How much of that reaches everyday practice, and when, remains open.
The book ages. It stands on research that moves fast. Some of the claims about drugs and vaccines will be rewritten within a few years, which the author himself admits.
Protocols or Super Agers?
| Protocols (Huberman) | Super Agers (Topol) | |
|---|---|---|
| Genre | A manual with numbered routines | An argument backed by studies |
| Main question | What to do this morning and evening | Why we age and what can be caught early |
| Strength of evidence | Mixed, from large studies to small | Mostly large studies and meta-analyses |
| Reading effort | Low, easy to dip into | Higher, technical language |
| For whom | Anyone starting with habits | Anyone wanting to understand prevention by data |
The two books complement each other. Protocols tells you what to do; Super Agers explains why and how to measure it.
What to take from the book right now
- Know your inflammation and lipid markers. High-sensitivity CRP, ApoB and lipoprotein(a) are among the numbers Topol treats as the basis of prevention, and in many countries you can get them measured without a referral.
- Take immunity seriously. Adult vaccination, including the shingles vaccine after fifty, is not only protection against an acute illness. The data from Wales suggests it may protect the brain too.
- Watch the trend, not single values. Organ clocks are not available yet, but the principle holds for ordinary tests: a value rising year after year says more than a single one above the reference range.
- Do not wait for a miracle. The best-documented tools in the final chapters are the familiar ones: movement including strength, a Mediterranean diet, sleep, social ties and not smoking.
Is Super Agers worth buying?
Yes, if you want to understand why prevention by data pays off and are willing to read slowly. It is the best-documented popular book on ageing of recent years, and the author has a rare position between the clinic and research. Scepticism belongs to the passages on artificial intelligence and on wider use of GLP-1 drugs. If you want routines rather than arguments, reach for Protocols; if you want to know what stands behind the routines, reach for Super Agers.
FAQ
What people ask
Who is Super Agers for?
Readers who want to understand why we age and what science can do about it, and who do not mind technical language. It is not a manual of routines like Protocols; it is an argument for why prevention pays and how to do it by data.
Who is Eric Topol?
An American cardiologist, founder of the Scripps Research Translational Institute and author of books on digital medicine. He is among the most cited physicians in the world and led the Wellderly study, which sequenced the genomes of healthy people over 80.
What is healthspan and why does the book build on it?
Healthspan is the years lived free of chronic disease and disability, as opposed to lifespan, the mere number of years. Topol argues that extending healthy years is a more realistic goal than extending life itself, and that we already have the tools.
What are organ clocks?
Estimates of the biological age of individual organs from proteins in the blood. A 2023 Stanford study showed that about one in five people has one organ ageing markedly faster than the rest of the body, and that such acceleration predicts disease of that organ. For now it is a research tool.
Does the book recommend GLP-1 drugs for healthy people?
No. It describes that in people with obesity they reduced the risk of cardiovascular events and that they dampen inflammation, and it speculates about wider use. For a healthy person without excess weight no recommendation follows.
Which edition should I get?
The original Super Agers: An Evidence-Based Approach to Longevity was published by Simon and Schuster in May 2025 and became a New York Times bestseller. A Czech translation, Superlétí, came out in September 2026 from Melvil.
Sources
What this article is based on
Peer reviewed papers and primary sources the text draws on. Links go to the original.
- Simon and Schuster: Super Agers, An Evidence-Based Approach to Longevity (Eric Topol, 2025)Original edition, published May 2025, ISBN 9781668067666.
- Erikson GA et al.: Whole-Genome Sequencing of a Healthy Aging Cohort. Cell, 2016The Wellderly study: genomes of 1,354 healthy people over 80, no special protective variants.
- Eyting M et al.: A natural experiment on the effect of herpes zoster vaccination on dementia. Nature, 2025Wales: shingles vaccination reduced new dementia diagnoses by about a fifth over seven years.
- Oh HSH et al.: Organ aging signatures in the plasma proteome track health and disease. Nature, 2023Organ clocks from blood proteins; accelerated ageing of one organ in a fifth of people.
- Lincoff AM et al.: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 2023The SELECT trial: a fifth fewer major cardiovascular events in people with obesity without diabetes.
- Healio: Book review, Super Agers, a timely guide to the science of healthy longevity (2025)Professional review: structure of the book, strong and weaker parts.
- Melvil Publishing: Superlétí, Czech edition of Super Agers (2026)Czech translation, 432 pages, published 22 September 2026.